• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Research Studies / A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)-SELECT-PsA1

June 27, 2018 By Arthritis Center

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

IRB: IRB00151158

Purpose of Study: This research study is being done to compare the effectiveness of either 15 or 30 mg once daily of upadacitinib versus adalimumab versus a placebo to control the signs and symptoms of psoriatic arthritis in patients who have failed at least one non-biologic disease modifying anti-rheumatic drug.

Eligibility Criteria:

  • Diagnosed with psoriatic arthritis for at least 6 months
  • Active psoriatic arthritis
  • History of or currently taking a DMARD (e.g. methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine)
  • No history of ever taking a biologic medication
  • Men and women 18 years and older

Study Status:

Recruiting

Specialty Center:

Arthritis Center

Coordinator/Contact:

Marilyn C. Towns, BSc, CCRP

Principal Investigator:

Ana-Maria Orbai, MD, MHS
Assistant Professor of Medicine

Dr. Orbai joined the Johns Hopkins Arthritis Center and is actively involved in patient care with a predominant focus on psoriatic arthritis and rheumatoid arthritis. Her research efforts seek to understand, from patients, how they experience arthritis in their lives. This knowledge will build the foundation for choosing and designing measures of disease activity and health related quality of life measures that can be used to improve the care and outcomes of people with arthritis.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Arthritis Research

  • Research Information
  • Patient-Centered Outcomes Research
  • Current Research Studies
  • Support Our Research
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy